McCarter & English, LLP
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β-hydroxyandrostan-17-one oxime in an amount of 0.1-10% by weight of the total weight of the composition; and a vehicle comprising (a) 45-100% of a monoester; (b) optionally up to 51% of a diester; and (c) optionally up to about 10% of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepatic encephalopathy by the use of a pharmaceutical formulation as claimed.
Umecrine Cognition AB
A A A A A A A A A A A
A61K A61P A61K A61K A61P A61K A61K A61K A61K A61K A61K
inventional inventional inventional inventional inventional additional inventional inventional inventional additional inventional
Maja Magnus Nicolaas Paul Thomas
Johansson Doverskog Schipper Alhadeff Meijer